Investigational drug · Phase 2
RSO-021
Also called: Thiostrepton
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "RSO-021"
First trial start
2022
Mar 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RSO-021", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Pleural Effusion
- Malignant Pleural Mesothelioma
- Mesothelioma
- Mesotheliomas Pleural
- Mesothelioma; Lung
- Pleural Effusion, Malignant
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RSO-021" as an intervention, largest first.
RS Oncology LLCIndustry
NCT05278975 · 50 participants · Start Mar 31, 2022 · Primary completion Nov 30, 2025
Drug: RSO-021 · For: Malignant Pleural Effusion; Malignant Pleural Mesothelioma; Mesothelioma and 3 more
Sites: Bristol, United Kingdom; Leeds, United Kingdom; North Shields, United Kingdom · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Iron starvation induced by vacidobactin A impairs the growth of pyoverdine-deficient Pseudomonas aeruginosa.
Kaur M, Chan DCK, Wardere H, et al. · Microbiol Spectr 2026
- Comprehensive derivatization of thiostrepton via heterologous expression.
Ikeda H, Hashimoto J, Kozone I, et al. · J Antibiot (Tokyo) 2026
- Artificial Intelligence-Guided Phenotypic Drug Repurposing Against Streptococcus pneumoniae.
Fitch JS, Ariadi MD, Kwun MJ, et al. · Adv Sci (Weinh) 2026
- CD155 regulates tumor growth and susceptibility to T cell mediated killing in diffuse midline glioma.
Tzaridis T, Fernández EC, Eisemann T, et al. · Neuro Oncol 2026
- Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.
Gibson V, Dzialo J, Messier T, et al. · Nat Commun 2026
- Structural Insights into the Cyclic Peptide Antibiotic Thiostrepton via NMR Spectroscopy.
Pradhan BL, Sen P, Ghosh P, et al. · J Phys Chem A 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.